When the (https://www.cnbc.com/2026/05/06/novo-nordisk-ceo-mike-doustdar-ozempic-maker-looking-for-deals.html) declares they're "more active than ever" hunting deals, that's not confidence talking — that's panic. Companies riding cash cows like Ozempic and Wegovy typically buy growth when they're winning. But when $LLY is gaining ground and your obesity drug fortress starts showing cracks?

Research these companies